Q9H7Z6 (KAT8_HUMAN) Homo sapiens (Human)
Histone acetyltransferase KAT8 UniProtKBInterProSTRINGInteractive Modelling
458 aa; Sequence (Fasta) ; (Isoform 2)
It is possible new templates exist for this target since these models were created.
Available Structures
31 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN DOSAGE COMPENSATION FACTORS MSL1 AND MOF |
Heteromer Q6PDM1; | 4×ACO; 4×ZN; | ||||
| Assess | ||||||
| Crystal structure of human MOF in complex with MSL1 |
Heteromer Q68DK7; | 1×ZN; | ||||
| Assess | ||||||
| Structural and mechanistical studies of the nuclear import by Importin-alpha |
Heteromer P52292; | |||||
| Assess | ||||||
| Human MYST histone acetyltransferase 1 | monomer | 1×ZN; 1×1VU; 1×CL; 4×EDO; | ||||
| Assess | ||||||
| Crystal structure of apo-form human MOF catalytic domain | monomer | 1×ZN; | ||||
| Assess | ||||||
| MYST histone acetyltransferase KAT6A/B in complex with WM-1119 | monomer | 1×FCV; 1×ZN; 1×MG; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 60 | monomer | 1×ML7; 1×ZN; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor CTX-124143 | monomer | 1×ZN; 1×MQJ; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 63 | monomer | 1×ZN; 1×MLV; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 34 | monomer | 1×ZN; 2×GOL; 1×MLS; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor | monomer | 1×CL; 1×ZN; 5×GOL; 1×NA; 1×7KM; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 83 | monomer | 1×ZN; 1×NA; 2×GOL; 1×SO4; 1×O9A; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with Acetyl-CoA cofactor | monomer | 1×ZN; 3×NA; 1×ACO; 1×7L1; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 42 | monomer | 1×ZN; 1×NA; 2×GOL; 1×SO4; 1×O9P; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 92 | monomer | 1×ZN; 2×GOL; 1×NBJ; 1×DMS; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 62 | monomer | 1×ZN; 1×MNJ; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 41 | monomer | 1×ZN; 1×NA; 1×O9S; 2×GOL; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 40 | monomer | 1×ZN; 1×NA; 2×GOL; 1×SO4; 1×O9V; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 55 | monomer | 1×ZN; 1×NA; 2×GOL; 1×SO4; 1×O9Y; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 80 | monomer | 1×ZN; 1×NA; 2×GOL; 1×SO4; 1×O9M; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 74 | monomer | 1×ZN; 1×NA; 2×GOL; 1×SO4; 1×O9J; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 39 | monomer | 1×ZN; 1×NA; 2×GOL; 1×O9D; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 60 | monomer | 1×ZN; 1×NA; 2×GOL; 1×O9G; | ||||
| Assess | ||||||
| MYST histone acetyltransferase 1 | monomer | 1×ZN; 1×COA; 13×UNX; | ||||
| Assess | ||||||
| Crystal structure of MYST acetyltransferase domain in complex with inhibitor 85 | monomer | 1×ZN; 1×NB7; 1×GOL; | ||||
| Assess | ||||||
| Human MYST histone acetyltransferase 1 | monomer | 1×ZN; 1×CL; 1×ACO; | ||||
| Assess | ||||||
| Human MOF C316S, E350Q crystal structure | monomer | 1×ZN; 2×CL; 2×NA; | ||||
| Assess | ||||||
| The Crystal Structure of human MYST1 from Biortus. | monomer | 1×ZN; 1×GOL; | ||||
| Assess | ||||||
| Human MOF K274P crystal structure | monomer | 1×ZN; 2×CL; | ||||
| Assess | ||||||
| Human MOF E350Q crystal structure with active site lysine partially acetylated | monomer | 1×ZN; 1×CL; | ||||
| Assess | ||||||
| Human MOF crystal structure with active site lysine partially acetylated | monomer | 1×ZN; 2×CL; 2×EDO; | ||||
| Assess | ||||||
2 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7cmr.1.A | monomer | 0.86 | 1×ZN; | 100.00 | ||
| Assess | ||||||
| 4x34.2.A | monomer | 0.56 | 10.71 | |||
| Assess | ||||||
2 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 7cmr.1.A | monomer | 0.84 | 1×ZN; | 97.30 | |
| Assess | ||||||
| Isoform 2 | 4x34.2.A | monomer | 0.53 | 10.71 | ||
| Assess | ||||||